Support for Patients using Commercial or Private Insurance

Helping Patients Afford TREMFYA™

Support for Patients using Commercial or Private Insurance

Janssen CarePath Savings Program for TREMFYA™

Your eligible patients will pay just $5 for each injection, with a $20,000 maximum program benefit each calendar year. The Janssen CarePath Savings Program provides financial assistance to help patients with their out-of-pocket costs on their TREMFYA™ medication, including: deductible, co-payment, and coinsurance costs. The Savings Program provides benefits when using either Medical or Pharmacy insurance coverage. Eligible patients must use commercial or private health insurance that covers a portion of their medication costs for TREMFYA™. Patients using Medicare, Medicaid, or other federally funded programs to pay for TREMFYA™ medication are not eligible to participate.

Learn more about the Janssen CarePath Savings Program, including full eligibility requirements.

Get your patients started today:

Patients can go online to enroll and activate their Janssen CarePath Savings Program card.
Patients may also "Print a Card" directly from this Web site if they should need one.

If your patients' pharmacy is unable to process their Savings Card, or if you choose to obtain TREMFYA™ for your patients, they can complete, sign and return the rebate form, with the required proof of purchase, to receive a rebate check from the Janssen CarePath Savings Program. Click here to get the rebate form.

Support for patients using government insurance or patients without insurance coverage

JanssenPrescriptionAssistance.com provides information on affordability programs and up-to-date information about independent foundations that may have available funding to help minimize medication costs for TREMFYA™.

Other Resources

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) provides free prescription medications to eligible individuals without insurance coverage for their medications and those who do not have adequate financial resources to pay for them. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 1-800-652-6227 (9 AM to 6 PM ET) or visit the foundation Web site at www.JJPAF.org.

Indication

TREMFYA™ is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA™ is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA™ is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA™ after physician approval and proper training.

Important Safety Information For TREMFYA

Important Safety Information

Infections
TREMFYA™ may increase the risk of infection. Treatment with TREMFYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA™ until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA™. Initiate treatment of latent TB prior to administering TREMFYA™. Monitor patients for signs and symptoms of active TB during and after TREMFYA™ treatment. Do not administer TREMFYA™ to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA™.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA™ include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA™.  Provide the Medication Guide to your patients and encourage discussion.

067010-170208